Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
Expanded Access requests are only being considered in response to Individual Patient and Intermediate-Size Population EAP Investigational New Drug (IND) applications. Availability will depend on location.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| REGN4461 | Drug | To be provided by Regeneron |
|
Key Inclusion: N/A
Key Exclusion: N/A
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Requests for Expanded Access must be initiated by a treating physician. Physicians should contact | Contact | 844-734-6643 | Managedaccessrequests@regeneron.com |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008060 | Lipodystrophy |
| D052497 | Lipodystrophy, Congenital Generalized |
| ID | Term |
|---|---|
| D012875 | Skin Diseases, Metabolic |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D052439 | Lipid Metabolism Disorders |
Not provided
Not provided
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D008052 | Lipid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |